Eris Lifesciences Ltd Announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India
Ahmedabad, India - February 24, 2026 - Eris Lifesciences Limited (BSE: 540596; NSE: ERIS), a leading Indian branded formulations company, announced a strategic partnership with Natco Pharma Limited for the commercialization of Semaglutide in India. This collaboration reinforces Eris's commitment to expanding its leadership in the diabetes and metabolic care segment.Semaglutide, a GLP-1 receptor agonist, has gained global recognition as a transformative therapy for Type 2 diabetes and chronic weight management, demonstrating robust clinical outcomes in glycemic control and weight reduction. With India's rapidly growing diabetic population and increasing awareness of obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment.
Eris has established a strong presence in diabetology, supported by extensive specialist reach and engagement with endocrinologists and physicians across India. The addition of semaglutide is expected to strengthen Eris' portfolio in advanced diabetes therapies.
This collaboration combines Eris's commercial and diabetes franchise presence with Natco's manufacturing and regulatory expertise in complex formulations.
Strategic Partnership Details
Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market. The product launch is expected in March 2026, targeting Type 2 diabetes management.Leadership Commentary
Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, stated that the partnership reflects the company’s commitment to strengthening its diabetes franchise with innovative therapies. He added that Eris is well-positioned to drive adoption and enhance patient access in India and views this partnership as a long-term value driver.About Eris Lifesciences Ltd (BSE: 540596, NSE: ERIS)
Established in 2007, Eris is among the Top 20 pharma companies in India. The company has an annual branded formulations revenue of INR 3,000+ crore as per AWACS. Eris has a diversified presence across specialties including Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology, and Critical Care. Eris manufactures prescription products across various dosage forms in its 6 manufacturing facilities. The company markets these products across India through a network of approximately 5,000 stockists and 500,000+ retail pharmacies.Eris’ revenue and operating profit have grown 2.6x in the last 5 years, with FY25 revenue of INR 2,894 crore. The company has diversified its presence across geographies and therapeutic areas with an investment of approximately INR 4,000 crore over the last 3 years.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.